Testing for Blastomycosis, Coccidioidomycosis, and Histoplasmosis at a Major Commercial Laboratory, United States, 2019-2024

被引:0
作者
Benedict, Kaitlin [1 ]
Williams, Samantha L. [1 ]
Smith, Dallas J. [1 ]
Lindsley, Mark D. [1 ]
Lockhart, Shawn R. [1 ]
Toda, Mitsuru [1 ]
机构
[1] CDCP, Mycot Dis Branch, 1600 Clifton Rd NE,MS H24-9, Atlanta, GA 30329 USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 08期
关键词
blastomycosis; coccidioidomycosis; histoplasmosis; immunoenzyme techniques; mycology; ENHANCED SURVEILLANCE; ARIZONA; CARE; USA;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Blastomycosis, coccidioidomycosis, and histoplasmosis are environmentally acquired fungal diseases that clinically resemble bacterial and viral community-acquired pneumonia and require laboratory testing for diagnosis. Patients frequently present to primary care and experience diagnostic delays when a fungal etiology is not initially suspected. Current national-level public health surveillance for these diseases is limited and does not include laboratory data, so nationwide testing practices are unknown. Methods. We identified laboratory tests for blastomycosis, coccidioidomycosis, and histoplasmosis ordered during 1 March 2019-29 February 2024 and performed within a major national commercial laboratory system. We analyzed test results, patient and healthcare provider features, reasons for testing, and temporal trends. Results. Results included 5693 Blastomyces complement fixation tests (of those, 12% were positive), 71 858 immunodiffusion tests (0.1% positive), and 1186 serum enzyme immunoassay (EIA) tests (11% positive); 154 989 Coccidioides EIA immunoglobulin M results (5% positive) and 154 968 immunoglobulin G results (8% positive); and 46 346 Histoplasma complement fixation tests (30% positive), 49 062 immunodiffusion tests (1% positive), 35 506 serum EIA tests (4% positive), and 82 489 urine EIA tests (2% positive). Most histoplasmosis (58%-74%) and blastomycosis (42%-68%) tests were ordered from hospitals, whereas coccidioidomycosis tests were most frequently ordered by primary care providers (40%). A yearly average of 2727 positive tests were ordered by healthcare providers in states without public health surveillance for these diseases. Conclusions. Blastomycosis, coccidioidomycosis, and histoplasmosis are likely underdetected in primary care settings or by public health surveillance. Increased testing by primary care providers and expanded surveillance are needed to reduce disease burden.
引用
收藏
页数:9
相关论文
共 10 条
  • [1] Testing for Cryptococcosis at a Major Commercial Laboratory-United States, 2019-2021
    Benedict, Kaitlin
    Gold, Jeremy A. W.
    Dietz, Stephanie
    Anjum, Seher
    Williamson, Peter R.
    Jackson, Brendan R.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (07):
  • [2] Clinical Testing Guidance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis in Patients With Community-Acquired Pneumonia for Primary and Urgent Care Providers
    Smith, Dallas J.
    Free, Rebecca J.
    Thompson III, George R.
    Baddley, John W.
    Pappas, Peter G.
    Benedict, Kaitlin
    Gold, Jeremy A. W.
    Tushla, Lisa A.
    Chiller, Tom
    Jackson, Brendan R.
    Toda, Mitsuru
    CLINICAL INFECTIOUS DISEASES, 2023, 78 (06) : 1559 - 1563
  • [3] Health Care Providers' Testing Practices for Coccidioidomycosis and Histoplasmosis in Patients With Community-Acquired Pneumonia-United States, 2020
    Benedict, Kaitlin
    Li, Yiman
    Molinari, Noelle Angelique M.
    Jackson, Brendan R.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (02):
  • [4] Symptoms in Blastomycosis, Coccidioidomycosis, and Histoplasmosis Versus Other Respiratory Illnesses in Commercially Insured Adult Outpatients-United States, 2016-2017
    Benedict, Kaitlin
    Kobayashi, Miwako
    Garg, Shikha
    Chiller, Tom
    Jackson, Brendan R.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E4336 - E4344
  • [5] Investigating Asthma After Coccidioidomycosis Among Patients With Commercial Health Insurance, United States, 2017-2022
    Benedict, Kaitlin
    Smith, Dallas J.
    Haczku, Angela
    Zeki, Amir A.
    Hsu, Joy
    Toda, Mitsuru
    Kenyon, Nicholas J.
    Thompson III, George R.
    MYCOSES, 2025, 68 (02)
  • [6] Telemental Health Utilization in Commercial Health Insurance Plans in the United States From 2010 Through 2019
    Arifkhanova, Aziza
    Elhabr, Andrew
    Murray, Christian
    Khushalani, Jaya
    Neri, Antonio
    Kaminski, Jennifer
    Puddy, Richard W.
    Ayer, Turgay
    JOURNAL OF CLINICAL PSYCHIATRY, 2024, 85 (01)
  • [7] HIV Testing Before and During the COVID-19 Pandemic - United States, 2019-2020
    DiNenno, Elizabeth A.
    Delaney, Kevin P.
    Pitasi, Marc A.
    MacGowan, Robin
    Miles, Gillian
    Dailey, Andre
    Courtenay-Quirk, Cari
    Byrd, Kathy
    Thomas, Dominique
    Brooks, John T.
    Daskalakis, Demetre
    Collins, Nicoline
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (25): : 820 - 824
  • [8] Sexually Transmitted Infection Testing Among Unstably Housed, Sexually Active Persons With Human Immunodeficiency Virus in the United States, 2018-2019
    Marcus, Ruthanne
    Tie, Yunfeng
    Dasgupta, Sharoda
    Crim, Stacy M.
    Beer, Linda
    Williams, Samantha P.
    Weiser, John
    SEXUALLY TRANSMITTED DISEASES, 2022, 49 (12) : 841 - 843
  • [9] Changes in Commercial Insurance Claims for Contraceptive Services During the Beginning of the COVID-19 Pandemic d United States, January 2019-September 2020
    Curtis, Kathryn M.
    Kulkarni, Aniket D.
    Nguyen, Antoinette T.
    Zapata, Lauren B.
    Kortsmit, Katherine
    Smith, Ruben A.
    Whiteman, Maura K.
    WOMENS HEALTH ISSUES, 2024, 34 (02) : 186 - 196
  • [10] Sexually Transmitted Infection Testing Among Transgender Women Living with Human Immunodeficiency Virus in the United States: Medical Monitoring Project, 2015-2019
    Town, Katy
    Tie, Yunfeng
    Dasgupta, Sharoda
    Kirkcaldy, Robert D.
    Crim, Stacy M.
    Weiser, John
    Bernstein, Kyle
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (05) : 899 - 902